{"id":35027,"date":"2025-12-18T10:30:43","date_gmt":"2025-12-18T09:30:43","guid":{"rendered":"https:\/\/www.thema-med.com\/?p=35027"},"modified":"2025-12-22T15:00:53","modified_gmt":"2025-12-22T14:00:53","slug":"breakthrough-devices-btx-new-opportunities-for-medtech-innovation-in-europe","status":"publish","type":"post","link":"https:\/\/www.thema-med.com\/en\/2025\/12\/18\/breakthrough-devices-btx-new-opportunities-for-medtech-innovation-in-europe\/","title":{"rendered":"Breakthrough Devices (BtX): New Opportunities for MedTech Innovation in Europe"},"content":{"rendered":"

Translated with AI<\/p>\n

On December 16, 2025, the European Commission published the new guidance<\/strong> MDCG 2025-9 on \u201cBreakthrough Devices (BtX)\u201d<\/strong><\/a>. The objective is to promote and facilitate the market entry of highly innovative Medical Devices and in vitro<\/em> diagnostic Medical Devices intended for the treatment of serious diseases or health conditions<\/strong>, without compromising safety and clinical evidence.<\/p>\n

This initiative represents a major step toward extending advanced medical technology to those in need by streamlining complex bureaucratic procedures that risk making such products marginal or inaccessible.<\/p>\n

Practical implementation will begin with a Pilot Project scheduled for launch in Q2 2026<\/strong> (April, May, June 2026).<\/b><\/p>\n

What is a BtX? Selection Criteria<\/strong><\/h3>\n

Not all innovative devices qualify as Breakthrough Devices. To fall under this guidance, a medical device or IVD must meet all the following requirements:<\/p>\n

    \n
  1. Novelty:<\/strong> it must introduce a high degree of innovation in technology and clinical procedure, representing a technological or clinical leap compared to the “State of the Art”<\/strong> (e.g., new mechanisms of action, revolutionary materials, or advanced AI algorithms).<\/li>\n
  2. Significant Clinical Impact:<\/strong> the device is expected to offer a positive clinical impact on patients or public health by:
    \n– Significantly outperforming the performance of current therapies<\/strong> and the State of the Art;
    \nOR
    \n<\/b>– Addressing an <\/strong>unmet medical need<\/b> that has remained unanswered due to the lack or ineffectiveness of existing therapeutic options.<\/span><\/span><\/span><\/li>\n
  3. Critical Target<\/b>: it must be intended for life-threatening or irreversibly debilitating conditions.<\/li>\n<\/ol>\n

    Data Rebalancing<\/strong><\/h3>\n

    The core of MDCG 2025-9 lies in the concept of \u201cData Rebalancing\u201d<\/strong>. This approach recognizes that, for radically new technologies, collecting comprehensive pre-market clinical evidence may be ethically or technically challenging.<\/p>\n

    Key Principle:<\/strong> The guidance allows for the certification of a device by accepting “residual clinical uncertainty”<\/strong> at the time of CE marking, provided it is compensated by extremely rigorous post-market surveillance.<\/p>\n

    Companies must be prepared to manage:<\/p>\n